tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
ARQT
Arcutis Biotherapeutics
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
Chart
Earnings
Dividends
Ownership
Financials
News & Insights
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding ARQT?
Track your performance easily
Link Broker

Arcutis Biotherapeutics (ARQT) Stock News & Sentiment

713 Followers
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
Premium
Press Releases
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
19h ago
ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14d ago
ARQT
Arcutis Biotherapeutics (ARQT) Riding High on Psoriasis Treatment
Premium
Market News
Arcutis Biotherapeutics (ARQT) Riding High on Psoriasis Treatment
23d ago
ARQT
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Premium
Press Releases
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29d ago
ARQT
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Premium
Press Releases
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
1M ago
ARQT
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Premium
Press Releases
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
1M ago
ARQT
ARQT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ARQT Upcoming Earnings Report: What to Expect?
1M ago
ARQT
More ARQT News >

ARQT News on the Web

Arcutis Announces Publication of ZORYVE® Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
Yahoo Finance
Neutral
Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc
Yahoo Finance
Neutral
Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
GuruFocus News
Neutral
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo Finance
Neutral
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
Yahoo Finance
Neutral
Arcutis Biotherapeutics, Inc. : This Small-Cap Healthcare Stock Is A Good Buy Right Now
Yahoo Finance
Neutral
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
Yahoo Finance
Neutral
Exploring Three High Growth Tech Stocks In The United States
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
ARQT
Sector Average
Media Buzz
This Week1 articles
Weekly Average2 articles
News Sentiment
This Week50%
Sector Average60%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARQT’s Media Buzz Sentiment?
1 articles about ARQT were published this week. In an average week, 2 articles are published.
    What is ARQT’s weekly average amount of articles?
    In an average week, 2 articles about ARQT are published.
      What is ARQT’s News Sentiment?
      50% of articles about ARQT were positive this week, compared to its sector average of 60%.
        Healthcare Stocks that are Trending in the News
        NUVLNuvalent
        BLCOBausch + Lomb Corporation
        INCYIncyte
        ACRVAcrivon Therapeutics, Inc.
        EWTXEdgewise Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing